Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study)

被引:147
作者
Saag, Kenneth G. [1 ]
Fitz-Patrick, David [2 ]
Kopicko, Jeff [3 ]
Fung, Maple [4 ]
Bhakta, Nihar [4 ]
Adler, Scott [6 ]
Storgard, Chris [4 ]
Baumgartner, Scott [5 ]
Becker, Michael A. [7 ]
机构
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] East West Med Res Inst, Honolulu, HI USA
[3] Receptos Inc, San Diego, CA USA
[4] Fate Therapeut, San Diego, CA USA
[5] Ardea Biosci, San Diego, CA USA
[6] AstraZeneca, Gaithersburg, MD USA
[7] Univ Chicago, Chicago, IL USA
关键词
HYPERURICEMIA; FEBUXOSTAT; TRIAL; SAFETY; URATE; PREVENTION; GUIDELINES; MANAGEMENT; INHIBITOR; MORTALITY;
D O I
10.1002/art.39840
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Lesinurad is a selective uric acid reabsorption inhibitor used for the treatment of gout in combination with a xanthine oxidase inhibitor. The Combining Lesinurad with Allopurinol Standard of Care in Inadequate Responders (CLEAR 1) study, a 12-month, multicenter, randomized, double-blind, placebo-controlled phase III trial, was conducted to investigate daily lesinurad (200 mg or 400 mg orally) added to allopurinol versus placebo plus allopurinol in patients with serum urate (UA) levels above a target of <6.0 mg/dl. Methods Patients receiving >= 300 mg of allopurinol (>= 200 mg in those with moderate renal impairment) who had serum UA levels >= 6.5 mg/dl at screening and >= 2 gout flares during the previous year were studied. The primary end point was the proportion of patients achieving a serum UA level of <6.0 mg/dl at month 6. Key secondary end points were the mean gout flare rate requiring treatment (months 7-12) and the proportions of patients with complete resolution of >= 1 target tophus (month 12). Safety assessments included adverse events and laboratory data. Results The study patients (n=603) were predominantly male and had a meanSD age of 51.9 +/- 11.3 years, a gout duration of 11.8 +/- 9.4 years, a baseline serum UA level of 6.94 +/- 1.27 mg/dl, and were receiving an allopurinol dosage of 306.6 +/- 59.58 mg/day. Lesinurad at doses of 200 mg or 400 mg added to allopurinol therapy significantly increased the proportions of patients who achieved serum UA target levels by month 6 as compared with those receiving allopurinol alone (54.2%, 59.2%, and 27.9%, respectively, P < 0.0001). Lesinurad was not significantly superior to allopurinol alone in terms of the secondary end points: rates of gout flares and complete resolution of tophi. Lesinurad was generally well-tolerated; the safety profile of the 200-mg dose was comparable to that of allopurinol alone, except for higher incidences of predominantly reversible elevations of serum creatinine levels. Conclusion Lesinurad added to allopurinol provided benefit as compared with allopurinol alone in reducing serum UA levels and represents a new treatment option for patients needing additional urate-lowering therapy.
引用
收藏
页码:203 / 212
页数:10
相关论文
共 33 条
  • [1] Ardea Biosciences, LES COMB XANTH OX IN
  • [2] Uricosuric drugs: the once and future therapy for hyperuricemia?
    Bach, Mary H.
    Simkin, Peter A.
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2014, 26 (02) : 169 - 175
  • [3] Febuxostat compared with allopurinol in patients with hyperuricemia and gout
    Becker, MA
    Schumacher, HR
    Wortmann, RL
    MacDonald, PA
    Eustace, D
    Palo, WA
    Streit, J
    Joseph-Ridge, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) : 2450 - 2461
  • [4] An open-label, 6-month study of allopurinol safety in gout: The LASSO study
    Becker, Michael A.
    Fitz-Patrick, David
    Choi, Hyon K.
    Dalbeth, Nicola
    Storgard, Chris
    Cravets, Matt
    Baumgartner, Scott
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2015, 45 (02) : 174 - 183
  • [5] The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
    Becker, Michael A.
    Schumacher, H. Ralph
    Espinoza, Luis R.
    Wells, Alvin F.
    MacDonald, Patricia
    Lloyd, Eric
    Lademacher, Christopher
    [J]. ARTHRITIS RESEARCH & THERAPY, 2010, 12 (02)
  • [6] Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group
    Bellomo, R
    Ronco, C
    Kellum, JA
    Mehta, RL
    Palevsky, P
    [J]. CRITICAL CARE, 2004, 8 (04): : R204 - R212
  • [7] Renal Transport of Uric Acid: Evolving Concepts and Uncertainties
    Bobulescu, Alexandru
    Moe, Orson W.
    [J]. ADVANCES IN CHRONIC KIDNEY DISEASE, 2012, 19 (06) : 358 - 371
  • [8] Febuxostat: a new treatment for hyperuricaemia in gout
    Edwards, N. Lawrence
    [J]. RHEUMATOLOGY, 2009, 48 : 15 - 19
  • [9] RANDOMIZED TRIAL OF ALLOPURINOL IN THE PREVENTION OF CALCIUM-OXALATE CALCULI
    ETTINGER, B
    TANG, A
    CITRON, JT
    LIVERMORE, B
    WILLIAMS, T
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (22) : 1386 - 1389
  • [10] Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia
    Fleischmann, Roy
    Kerr, Bradley
    Yeh, Li-Tain
    Suster, Matt
    Shen, Zancong
    Polvent, Elizabeth
    Hingorani, Vijay
    Quart, Barry
    Manhard, Kimberly
    Miner, Jeffrey N.
    Baumgartner, Scott
    [J]. RHEUMATOLOGY, 2014, 53 (12) : 2167 - 2174